Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Collaboration symbols : Aveo save search
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Eli Lilly and Company for ERBITUX® (cetuximab) in North America to Evaluate Ficlatuzumab and Cetuximab in Patients with Recurrent or Metastatic HNSCC
Published: 2022-06-22 (Crawled : 12:00) - investor.aveooncology.com
LLY | News | $726.31 -2.63% -0.04% 3.5M
|
Health Technology
|
| O: 1.31%
H: 0.0%
C: 0.0%
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: 8.59%
H: 9.93%
C: 5.88%
erbitux america collaboration trial agreement
Actinium Pharmaceuticals, Inc. and AVEO Oncology Enter Research Collaboration Agreement to Develop First-in-Class Actinium-225 ErbB3 Targeting Radiotherapy for Solid Tumors
Published: 2022-02-22 (Crawled : 18:00) - biospace.com/
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: -0.58%
H: 1.18%
C: -1.18%
ATNM | $6.85 2.7% 0.0% 350K
|
Health Technology
|
| O: -1.18%
H: 3.39%
C: 0.2%
als solid tumors research therapy collaboration iot
NiKang Therapeutics and AVEO Oncology Announce a Clinical Trial Collaboration and Supply Agreement to Evaluate the Combination of NKT2152, a HIF2α Inhibitor, and FOTIVDA® (tivozanib) for the Treatment of Advanced Clear Cell Renal Cell Carcinoma
Published: 2022-01-05 (Crawled : 14:30) - biospace.com/
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: -1.92%
H: 0.0%
C: -12.16%
nkt2152 fotivda treatment renal trial therapeutics cel collaboration cell carcinoma
AVEO Oncology Announces Clinical Trial Collaboration and Supply Agreement with Merck KGaA, Darmstadt, Germany to Evaluate Ficlatuzumab and ERBITUX® (cetuximab) in Patients with Recurrent or Metastatic HNSCC
Published: 2022-01-04 (Crawled : 23:00) - biospace.com/
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: -1.33%
H: 0.0%
C: 0.0%
erbitux trial germany collaboration
AVEO Oncology Announces Collaboration with Bristol Myers Squibb to Evaluate FOTIVDA® (tivozanib) in Combination with OPDIVO® (nivolumab) in Pivotal Phase 3 TiNivo-2 Trial in IO Relapsed Renal Cell Carcinoma
Published: 2021-03-12 (Crawled : 13:00) - biospace.com/
AVEO | $15.0 0.0% 0
|
Health Technology
|
| O: 4.74%
H: 6.25%
C: 0.06%
renal collaboration announces collaboration phase 3 trial cell carcinoma nivolumab
Gainers vs Losers
| 67% | 33% |
Top 10 Gainers
AGBA | News | $1.26 215.0% 68.25% 130M
|
Finance
EGOX | $0.0515 43.06% 30.1% 330M
|
OLB 4 | $0.33 -14.95% 25.53% 840K
|
Technology Services
NVFY | $2.77 31.28% 23.83% 33M
|
Consumer Durables
ZCMD | $1.87 28.97% 22.46% 31M
|
Commercial Services
RCON | $0.1112 13.01% 21.28% 1.7M
|
Distribution Services
INSG | $3.03 25.21% 20.13% 330K
|
Electronic Technology
GCTK | $0.8191 22.25% 18.2% 190K
|
Manufacturing
WLGS | $0.59 18.0% 17.9% 2.3M
|
ASNS | $0.828 21.75% 17.86% 18K
|
Your saved searches
Save your searches and get alerts when important news are released.